Amyloidosis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Amyloidosis – Drugs In Development, 2023’, provides an overview of the Amyloidosis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Amyloidosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Amyloidosis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Amyloidosis
- The report reviews pipeline therapeutics for Amyloidosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Amyloidosis therapeutics and enlists all their major and minor projects
- The report assesses Amyloidosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Amyloidosis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Amyloidosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Amyloidosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
3SBio IncAbbVie Inc
ADEL Inc
ADRx Inc
Affiliated Hospital of Xuzhou Medical University
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Alzheon Inc
Amgen Inc
Amyl Therapeutics
Assertio Therapeutics Inc
Attralus Inc
Autotac Bio Inc
BELLUS Health Inc
BridgeBio Pharma Inc
Bristol-Myers Squibb Co
BSIM Therapeutics SA
Corino Therapeutics Inc
Covalent Bioscience Inc
Dren Bio Inc
Elsie Biotechnologies Inc
Eterna Therapeutics Inc
GSK plc
HaemaLogix Pty Ltd
Hangzhou Sumgen Biotech Co Ltd
Huazhong University of Science & Technology
Illimis Therapeutics Inc
IMMvention Therapeutix Inc
Ionis Pharmaceuticals Inc
IRCCS Policlinico San Matteo
Johnson & Johnson
Lotus Pharmaceutical Co Ltd
Mabpharm Ltd
Millennium Pharmaceuticals Inc
Mitsubishi Tanabe Pharma Corp
Nanjing University
Nexcella Inc
Novo Nordisk AS
Paradox Immunotherapeutics Inc
Proclara Biosciences Inc
Prothena Corp Plc
R-Pharm
Recordati SpA
Regeneron Pharmaceuticals Inc
ResQ Biotech
Sanofi
Shanghai YaKe Biotechnology Co Ltd
Sirnaomics Ltd
SOLA Biosciences LLC
Sorrento Therapeutics Inc
Swedish Orphan Biovitrum AB
The Scripps Research Institute
University of California Los Angeles
Yaotang (Shanghai) Biotechnology Co Ltd